

Generic blood cancer drug launched by Natco

10 May 2017 | News

Natco Pharma will market generic pomalidomide capsules under its brand name Pomalid in India.



Natco Pharma has launched a generic version of pomalidomide capsules, used in treatment of a type of blood cancer, in India.

Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Multiple myeloma is a cancer formed by malignant plasma cells.

Natco has launched pomalidomide capsules in strengths of 1 mg, 2 mg and 4 mg in India. Pomalidomide is sold by Celgene Inc., in the USA, under the brand name POMALYST.

Natco Pharma will market generic pomalidomide capsules under its brand name Pomalid in India.

Natco Pharma addresses opportunities across the oncology, CNS, gastrointestinal, migraine and anti-depressant segments, each of which is growing in size and scope.